KRAS and mucinous neoplasm: Age, gender, synchronous or metachronous metastases, preoperative laparotomy or laparoscopy, PCI ≥ 20, TN-stage, primary tumour location, mucinous tumors, grade of differentiation, and the presence of KRAS or BRAF mutations were also analyzed but none was significantly associated with lead time.